Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials

Reuters

2025/07/05

Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials

Onco-Innovations Ltd. has announced an agreement with Nucro-Technics Inc. to conduct IND-enabling studies for the company's lead drug candidate, NP/A83 (OI-83463), a polymer-encapsulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This collaboration involves extensive preclinical testing to evaluate the drug's bioavailability, biodistribution, and pharmacokinetics, as well as its safety through Good Laboratory Practice $(GLP)$ toxicology studies. These efforts are aimed at supporting an Investigational New Drug $(IND.AU)$ application and the subsequent initiation of Phase I/II clinical trials for the treatment of advanced-stage, PTEN- or SHP-1-deficient cancers. The results of these studies, intended to meet both FDA and Health Canada standards, will be compiled for future regulatory submissions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1045951) on July 04, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2549450315"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549450315\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549450315?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-05 06:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549450315","market":"nz","top_or_hot":-1,"title":"Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Onco-Innovations Ltd. has announced an agreement with Nucro-Technics Inc. to conduct IND-enabling studies for the company's lead drug candidate, NP/A83 (OI-83463), a polymer-encapsulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This collaboration involves extensive preclinical testing to evaluate the drug's bioavailability, biodistribution, and pharmacokinetics, as well as its safety through Good Laboratory Practice <a href=\"https://laohu8.com/S/GLP\">$(GLP)$</a> toxicology studies. These efforts are aimed at supporting an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application and the subsequent initiation of Phase I/II clinical trials for the treatment of advanced-stage, PTEN- or SHP-1-deficient cancers. The results of these studies, intended to meet both FDA and Health Canada standards, will be compiled for future regulatory submissions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1045951) on July 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOnco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-05 06:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Onco-Innovations Ltd. has announced an agreement with Nucro-Technics Inc. to conduct IND-enabling studies for the company's lead drug candidate, NP/A83 (OI-83463), a polymer-encapsulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This collaboration involves extensive preclinical testing to evaluate the drug's bioavailability, biodistribution, and pharmacokinetics, as well as its safety through Good Laboratory Practice <a href=\"https://laohu8.com/S/GLP\">$(GLP)$</a> toxicology studies. These efforts are aimed at supporting an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application and the subsequent initiation of Phase I/II clinical trials for the treatment of advanced-stage, PTEN- or SHP-1-deficient cancers. The results of these studies, intended to meet both FDA and Health Canada standards, will be compiled for future regulatory submissions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1045951) on July 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4092","symbol_name":"石油与天然气钻井","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250704:nNDL5Dds1V:1","article_id":"2549450315","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549450315","pubTimestamp":1751666499,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials. Onco-Innovations Ltd. has announced an agreement with Nucro-Technics Inc. to conduct IND-enabling studies for the company's lead drug candidate, NP/A83 , a polymer-encapsulated Polynucleotide Kinase Phosphatase  inhibitor. This collaboration involves extensive preclinical testing to evaluate the drug's bioavailability, biodistribution, and pharmacokinetics, as well as its safety through Good Laboratory Practice  toxicology studies. These efforts are aimed at supporting an Investigational New Drug  application and the subsequent initiation of Phase I/II clinical trials for the treatment of advanced-stage, PTEN- or SHP-1-deficient cancers. The results of these studies, intended to meet both FDA and Health Canada standards, will be compiled for future regulatory submissions.Disclaimer: This news brief was created by Public Technologies  using generative artificia","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300347":"泰格医药","BK4092":"石油与天然气钻井","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0028":"国家队","PTEN":"Patterson-UTI Energy","BK0216":"研究试验","BK0174":"增持","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0077":"质押式回购"},"translate_title":"Onco-Innovations Ltd.与Nucro-Technics启动PNKP抑制剂的关键临床前研究，向人体试验迈进","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300347":0.9,"PTEN":0.9},"content_text":"Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials\n    \n\n        Onco-Innovations Ltd. has announced an agreement with Nucro-Technics Inc. to conduct IND-enabling studies for the company's lead drug candidate, NP/A83 (OI-83463), a polymer-encapsulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This collaboration involves extensive preclinical testing to evaluate the drug's bioavailability, biodistribution, and pharmacokinetics, as well as its safety through Good Laboratory Practice $(GLP)$ toxicology studies. These efforts are aimed at supporting an Investigational New Drug $(IND.AU)$ application and the subsequent initiation of Phase I/II clinical trials for the treatment of advanced-stage, PTEN- or SHP-1-deficient cancers. The results of these studies, intended to meet both FDA and Health Canada standards, will be compiled for future regulatory submissions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1045951) on July 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}